Malignant hyperthermia;Malign hypertermi - En arvelig og potensielt livstruende tilstand

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 20, 2005, Pages 2792-2794

  Haugen, Tonje ^a   Toft, Mathias ^b   Müller, Clemens R ^c   Aasly, Jan ^d  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; DANTROLENE; HALOGEN; ISOLEUCINE; NEUROMUSCULAR DEPOLARIZING AGENT; RYANODINE RECEPTOR; THREONINE;

ADULT; AMINO ACID SUBSTITUTION; ANESTHESIA COMPLICATION; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; DISEASE ASSOCIATION; DRUG EXPOSURE; GENE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERMETABOLISM; MALIGNANT HYPERTHERMIA; MEDICAL LITERATURE; MOLECULAR GENETICS; MORTALITY; MUSCLE CONTRACTURE; MYOPATHY; NORWAY; RISK REDUCTION; RYR1 GENE;

ADULT; DANTROLENE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE RELAXANTS, CENTRAL; MUTATION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 27644571941     PISSN: 00292001     EISSN: 00292001     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Denborough M. Malignant hyperthermia. Lancet 1998; 352: 1131-6.
2. Bendixen D, Skovgaard LT, Ording H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997; 41: 480-4.
3. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet 1960; 2: 45.
4. Denborough MA, Ebeling P, King JO. Myopathy and malignant hyperpyrexia. Lancet 1970; 1: 1138-40.
5. Fujii J, Otsu K, Zorzato F et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-51.
6. Zhang Y, Chen HS, Khanna VK et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5: 46-50.
7. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7.
8. Stovner J, Gjengsto H, Innes RK. Anestesimdusert malign hypertermi i Norge. Tidsskr Nor Lægeforen 1972; 92: 1256-60.
9. Fagerlund T, Ording H, Bendixen D. Search for three known mutations in the RYR1 gene in 48 Danish families with malignant hyperthermia. Clin Genet 1994; 46: 401-4.
10. Loke J, MacLennan DH. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med 1998; 104: 470-86.
11. Krause T, Gerbershagen MU, Fiege M et al. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-73.
12. Ording H, Brancadoro V, Cozzolino S et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-66.
13. Sei Y, Sambuughin NN, Davis EJ et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101: 824-30.
14. Monnier N, Procaccio V, Stieglitz P et al. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-25.
15. Urwyler A, Deufel T, McCarthy T et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7.
16. Lov 2003-12-05 nr. 100. Lov om humanmedisinsk bruk av bioteknologi m.m. (bioteknologiloven).
17. Davis MR, Haan E, Jungbluth H et al. Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 2003; 13: 151-7.
18. Araki M, Takagi A, Higuchi I et al. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology 1988; 38: 297-301.
19. Nielsen S, Lundemose JB, Simonsen MS et al. Letalt forløbende ecstasyforgiftning. Ugeskr Læger 2001; 163: 2253-5.
20. Fiege M, Wappler F, Weisshorn R et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine («ecstasy»). Anesthesiology 2003; 99: 1132-6.